Whole blood gene expression testing for coronary artery disease in nondiabetic patients: major adverse cardiovascular events and interventions in the PREDICT trial.

Thus, at most, 3 patients of 1,160 (0.3%) had both a low GES and an adverse event in the following year, yielding an NPV for events alone of 99.2%, although this did not reach statistical significance (OR = 2.41, 95% CI = 0.74–10.4, p = 0.16).

also in 111,027 other papers